egtazic acid has been researched along with cardiovascular agents in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ikejima, K; Qu, W; Thurman, RG; Waalkes, MP; Zhong, Z | 1 |
Brown, JT; Randall, AD | 1 |
Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A | 1 |
3 other study(ies) available for egtazic acid and cardiovascular agents
Article | Year |
---|---|
Glycine blocks the increase in intracellular free Ca2+ due to vasoactive mediators in hepatic parenchymal cells.
Topics: Adrenergic alpha-Agonists; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Agents; Cell Membrane; Cells, Cultured; Chloride Channels; Dinoprostone; Dose-Response Relationship, Drug; Egtazic Acid; Female; Gallic Acid; Glycine; Heparin; Liver; Phenylephrine; Rats; Rats, Sprague-Dawley | 2002 |
Activity-dependent depression of the spike after-depolarization generates long-lasting intrinsic plasticity in hippocampal CA3 pyramidal neurons.
Topics: Action Potentials; Animals; Anthracenes; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Signaling; Carbamates; Cardiovascular Agents; Chelating Agents; Egtazic Acid; Hippocampus; In Vitro Techniques; KCNQ Potassium Channels; Male; Membrane Potentials; Neuronal Plasticity; Patch-Clamp Techniques; Phenylenediamines; Pyramidal Cells; Pyrimidines; Rats; Rats, Wistar | 2009 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Cardiovascular Agents; Cells, Cultured; Chelating Agents; Chemokine CCL2; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Egtazic Acid; Enzyme Activation; Flavonoids; Humans; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Nifedipine; Phosphorylation; PPAR gamma; Protein Kinase Inhibitors; RNA Interference; RNA, Messenger; Time Factors; Transfection | 2010 |